RecruitingNCT07482176
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
PHASE3 · 534 planned enrolment
- Countries listed
- 1
- Registry update
- September 24, 2026
Program Identity
ADVM-022-13
Exact source-linked program identifier and related public trial registrations.
Adverum Biotechnologies, Inc.
ADVM-022-13
1 exact source-linked registration. No aliases, synonyms, ownership, or cross-source equivalence are inferred.